alexa
Reach Us +44-1647-403003
Lung Cancer Staging | OMICS International | Abstract
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Commentary

Lung Cancer Staging

Filipe Moreira de Andrade1*, Luiz Felippe Judice2, Paulo de Biasi3and Robert Cerfolio4
1Assistant Professor of Thoracic Surgery, Fluminense Federal University, Brazil
2Full Professor of Thoracic Surgery, Fluminense Federal University, Brazil
3Titular Professor of Thoracic Surgery, Fluminense Federal University, Brazil
4Professor of Thoracic Surgery, University of Alabama at Birmingham, James H. Estes Family Endowed Chair for Lung Cancer Research, USA
Corresponding Author : Filipe Moreira de Andrade
Department of Surgery
Division of Thoracic Surgery
Fluminense Federal University
Rua Visconde do Rio Branco, 755 / 812
Centro, Niterói-RJ, 24020-006, Brazil
Fax: +55 21 2719 5735
Tel: +55 21 9500 1503
E-mail: [email protected]
Received February 15, 2012; Accepted March 23, 2012; Published March 26, 2012
Citation: Andrade FM, Judice LF, de Biasi P, Cerfolio R (2012) Lung Cancer Staging. J Cancer Sci Ther S11:004. doi:10.4172/1948-5956.S11-004
Copyright: © 2012 Andrade FM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google

Abstract

Lung cancer incidence has dramatically risen in the past century. It is now the leading cause of cancer death in the world, both among men and women. Accurate staging is important because treatment options and prognosis differ significantly by stage. If there are no distant metastases, the status of mediastinal lymph nodes is the critical point to distinct between patients who will benefit from surgical therapy, neoadjuvant therapy or clinical treatment. Noninvasive imaging studies including chest computed tomography and positron emission tomography scanning should be performed in all patients who are potentially candidates to pulmonary resection. The findings of these noninvasive studies are critical, and the invasive mediastinal staging must be performed according to the medical examination and the results of noninvasive tests. In patients with extensive mediastinal infiltration by lung cancer, the disease is considered advanced and invasive staging is not needed. In patients with mediastinal lymph node enlargement seen at computed tomography, a sample tissue of these nodes is necessary. In these cases there are several methods to invasive staging the mediastinum, but mediastinoscopy is the gold standard. In patients with clinical T2 or with central tumors, invasive staging of the mediastinal nodes is necessary. Patients with a peripheral clinical T1 lung cancer do not usually need invasive confirmation of mediastinal nodes unless there is an abnormal standard uptake value in the nodes, found on positron emission tomography scanning. The staging of patients with left upper lobe tumors should include an assessment of the preaortic and aortopulmonary window lymph nodes. Pancoast tumors always need invasive mediastinal staging if they are considered for surgical resection.

Keywords

Share This Page
Top